BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

Royalty buys PTC royalty stream  Royalty Pharma plc (NASDAQ:RPRX) is spending $650 million to acquire from PTC Therapeutics Inc. (NASDAQ:PTCT) about 43% its royalties for spinal muscular atrophy therapy risdiplam, to which the biotech's entitled...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

Ovid’s gaboxadol meets in Phase II for Fragile X   Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to...
BioCentury | Apr 29, 2020
Product Development

Efficacy data for risdiplam could position Roche’s oral SMA therapy ahead of Spinraza

Even with a PDUFA delay for Roche’s SMA therapy earlier this month, efficacy data from the Phase II/III FIREFISH trial of risdiplam released Tuesday cast a favorable light on the oral therapy when compared with...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BioCentury | Apr 7, 2020
Regulation

FDA delays oral SMA therapy risdiplam as Roche readies submissions in China, EU

Roche’s oral therapy to treat spinal muscular atrophy faces a three-month delay after FDA pushed back its PDUFA date to review additional data, even as the pharma readies regulatory submissions in other territories. In November,...
BioCentury | Mar 26, 2020
Emerging Company Profile

ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology. The company was formed...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Feb 7, 2020
Product Development

Roche, PTC provide first look at pivotal SMA data in adults

Roche and PTC reported the first pivotal data for a spinal muscular atrophy therapy in adults with established disease on Thursday when they unveiled the detailed data supporting their bid for risdiplam to treat SMA...
Items per page:
1 - 10 of 418
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

Royalty buys PTC royalty stream  Royalty Pharma plc (NASDAQ:RPRX) is spending $650 million to acquire from PTC Therapeutics Inc. (NASDAQ:PTCT) about 43% its royalties for spinal muscular atrophy therapy risdiplam, to which the biotech's entitled...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

Ovid’s gaboxadol meets in Phase II for Fragile X   Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to...
BioCentury | Apr 29, 2020
Product Development

Efficacy data for risdiplam could position Roche’s oral SMA therapy ahead of Spinraza

Even with a PDUFA delay for Roche’s SMA therapy earlier this month, efficacy data from the Phase II/III FIREFISH trial of risdiplam released Tuesday cast a favorable light on the oral therapy when compared with...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BioCentury | Apr 7, 2020
Regulation

FDA delays oral SMA therapy risdiplam as Roche readies submissions in China, EU

Roche’s oral therapy to treat spinal muscular atrophy faces a three-month delay after FDA pushed back its PDUFA date to review additional data, even as the pharma readies regulatory submissions in other territories. In November,...
BioCentury | Mar 26, 2020
Emerging Company Profile

ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology. The company was formed...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Feb 7, 2020
Product Development

Roche, PTC provide first look at pivotal SMA data in adults

Roche and PTC reported the first pivotal data for a spinal muscular atrophy therapy in adults with established disease on Thursday when they unveiled the detailed data supporting their bid for risdiplam to treat SMA...
Items per page:
1 - 10 of 418